Background: Conspiracies about vaccination are prevalent. We assessed how the health information sources people rely upon and their political ideologies are associated with acceptance of vaccine conspiracies.
Methods: Online survey (N = 599) on Amazon's Mechanical Turk crowdsource platform. Hypotheses were tested via structural equation modeling.
Results: Acceptance of vaccine conspiracy beliefs was associated positively with greater reliance on social media for health information (coef. = 0.42, p < .001), inversely related to use of medical websites (coef. = -0.21, p < .001), and not significantly related to use of providers for health information (coef. = -0.13, p = .061). In addition, liberal political orientation was negatively associated with acceptance of vaccine conspiracies (coef. = -0.29, p < .001).
Conclusions: An understanding of vaccine conspiracy acceptance requires a consideration of people's health information sources. The greater susceptibility of political conservatives to conspiracy beliefs extends to the topic of vaccination.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.vaccine.2019.04.063 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Perspectives of healthcare workers on drone-enabled healthcare delivery in challenging terrains of Manipur and Nagaland, India: a qualitative research.
J Public Health Policy
January 2025
Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, 110029, India.
Collaborative initiatives of the drone industry and healthcare sector are becoming a pivotal step in restructuring healthcare service delivery in India. This paper documents knowledge and perceptions of healthcare workers from various districts of Manipur and Nagaland towards the use of drones for medical supply in the region. The study utilized 27 in-depth interviews with healthcare workers to collect qualitative data, which was then analyzed using NVivo 14 for thematic and content analysis.
View Article and Find Full Text PDFSafety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.
Hum Vaccin Immunother
December 2025
Crucell Integration, Janssen Research and Development, Beerse, Belgium.
We conducted a randomized, Phase 2 trial to assess the safety and humoral immunogenicity of reduced doses/dose volume of the standard dose of Ad26.COV2.S COVID-19 vaccine (5 × 10 viral particles [vp]) in healthy adolescents aged 12-17 years.
View Article and Find Full Text PDFAssessing COVID-19 Pandemic-Era Vaccine Uptake and Adherence to Prevention Measures: A Comparative Analysis Among Men and Women Using Lot Quality Assurance Sampling in Central Uganda.
Risk Manag Healthc Policy
January 2025
School of Public Health, Gudie University Project, Kampala, Uganda.
Aim: This study examined citizens' knowledge and compliance with COVID-19 standard operating procedures (SOPs), vaccine acceptance and hesitancy, and factors that could influence these behaviors.
Methods: The study that utilised the Lot Quality Assurance Sampling (LQAS) approach was conducted in eight districts of Central Uganda; Kiboga, Kyankwanzi, Mubende, Kasanda, Mityana, Luwero, Nakaseke, and Nakasongola districts. Each district was divided into five supervision areas (SAs).
Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial.
EClinicalMedicine
January 2025
Janssen Research and Development, Beerse, Belgium.
Background: Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration of Ad26.COV2.
View Article and Find Full Text PDFImmunogenicity and safety of a COVID-19 DNA vaccine in healthy adults and elderly: A randomized, observer-blind, placebo-controlled phase 2 trial.
Hum Vaccin Immunother
December 2025
Jiangsu Provincial Medical Innovation Center, National Health Commission Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention (Jiangsu Provincial Academy of Preventive Medicine), Nanjing, China.
INO-4800 represents a DNA-based vaccine encoding the spike protein of SARS-CoV-2. This phase 2 trial evaluated the immunogenicity and safety of INO-4800 as a primary vaccination series in adults. We conducted a randomized, observer-blind, placebo-controlled phase 2 trial of intradermal injection of INO-4800 in both healthy adults and elderly individuals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!